NCT06953349 Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis
| NCT ID | NCT06953349 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Barnet Dulaney Perkins Eye Centers |
| Condition | Open-Angle Glaucoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-03-31 |
| Primary Completion | 2025-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2025-03-31 with a primary completion date of 2025-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis
Eligibility Criteria
Inclusion Criteria: * Subjects with h/o CEIOL/OMNI/Hydrus (chosen based on subjects on more than 1 medication pre-operatively) with at least 3 years of follow up data * have Glaucoma Exclusion Criteria: * Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies. * Patients with refractory CME or CME persisting 3 months or more post-operatively * Patients with incomplete IOP, medication logs or VF data within post-operative period * Prior incisional surgery or MIGS
Contact & Investigator
Christine Funke, Medical Doctor
PRINCIPAL INVESTIGATOR
Barnet Dulaney Perkins Eye Centers
Frequently Asked Questions
Who can join the NCT06953349 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Open-Angle Glaucoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06953349 currently recruiting?
Yes, NCT06953349 is actively recruiting participants. Contact the research team at derek.arnson@researchavp.com for enrollment information.
Where is the NCT06953349 trial being conducted?
This trial is being conducted at Mesa, United States.
Who is sponsoring the NCT06953349 clinical trial?
NCT06953349 is sponsored by Barnet Dulaney Perkins Eye Centers. The principal investigator is Christine Funke, Medical Doctor at Barnet Dulaney Perkins Eye Centers. The trial plans to enroll 300 participants.